Eltrombopag (Revolade®) is indicated in adult patients with chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy
Rapid Review
Commenced | Completed | Outcome |
10/01/2014 | 13/02/2014 | Full Pharmacoeconomic Evaluation not Recommended. |